SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trial
Takahiro Masuda(Jichi Medical University), Yoshiyuki Morishita(Jichi Medical University), Marina Miura, Keiji Hirai(Jichi Medical University), Tetsu Akimoto(Jichi Medical University), Masato Morinari(Stony Brook School), Kazuyuki Shimada(Yamato Municipal Hospital), Maki Asakura-Kinoshita(Jichi Medical University), Daisuke Nagata(Jichi Medical University), Ken Ohara(Jichi Medical University), Kentaro Oka(Jichi Medical University), Masato Sakai(Jichi Medical University), Kyohei Misawa(Jichi Medical University)
Cited by 5
Related Papers
Morning Surge in Blood Pressure as a Predictor of Silent and Clinical Cerebrovascular Disease in Elderly Hypertensives
|Circulation|2003|1.2k
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
|American Journal of Physiology-Renal Physiology|2013|481
AMP-activated Protein Kinase (AMPK) Signaling in Endothelial Cells Is Essential for Angiogenesis in Response to Hypoxic Stress
|Journal of Biological Chemistry|2003|328
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
|American Journal of Physiology-Renal Physiology|2013|308
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
|American Journal of Physiology-Renal Physiology|2012|158